Condition: Multiple Myeloma in Relapse · Myeloma Multiple · Multiple Myeloma Progression · Sponsor: Kelonia Therapeutics, Inc.
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
This description comes directly from the study's public registry record.
SVP Clinical Development · 617-223-7349 · clinicaltrials@keloniatx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Providence Portland Medical Center | Portland, Oregon, United States | Recruiting |
| The Royal Prince Alfred | Camperdown, New South Wales, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| The Alfred Paula Fox Melanoma and Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07075185